Compare Bayer AG with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 1.21% and Operating profit at -6.41% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 36,497 Million ()
10.00
NA
0.00%
1.22
12.29%
1.27
Revenue and Profits:
Net Sales:
13,405 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,767 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.9%
0%
4.9%
6 Months
10.16%
0%
10.16%
1 Year
49.48%
0%
49.48%
2 Years
48.53%
0%
48.53%
3 Years
-21.6%
0%
-21.6%
4 Years
-31.49%
0%
-31.49%
5 Years
-22.83%
0%
-22.83%
Bayer AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.05%
EBIT Growth (5y)
98.12%
EBIT to Interest (avg)
2.34
Debt to EBITDA (avg)
3.73
Net Debt to Equity (avg)
1.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
5.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
8.66%
ROE (avg)
15.91%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.27
EV to EBIT
10.01
EV to EBITDA
7.09
EV to Capital Employed
1.12
EV to Sales
1.54
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
11.23%
ROE (Latest)
12.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
13,405.00
13,738.00
-2.42%
Operating Profit (PBDIT) excl Other Income
4,366.00
4,247.00
2.80%
Interest
679.00
584.00
16.27%
Exceptional Items
47.00
-552.00
108.51%
Consolidate Net Profit
2,767.00
1,304.00
112.19%
Operating Profit Margin (Excl OI)
232.20%
223.70%
0.85%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -2.42% vs -0.20% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 112.19% vs -34.87% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
45,575.00
46,606.00
-2.21%
Operating Profit (PBDIT) excl Other Income
11,009.00
8,529.00
29.08%
Interest
1,722.00
1,959.00
-12.10%
Exceptional Items
-6,413.00
-6,368.00
-0.71%
Consolidate Net Profit
-3,595.00
-2,546.00
-41.20%
Operating Profit Margin (Excl OI)
152.60%
96.10%
5.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.21% vs -2.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -41.20% vs 13.46% in Dec 2024
About Bayer AG 
Bayer AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






